Of the new instances, 476 are migrants living in dormitories, while five reported instances of networked painting are also foreigners with paint passes, the Ministry of Health (MS) said.
There are also 4 imported boxes, which were put into operation upon arrival in Singapore.
On Thursday, the Ministry of Health said the average number of new instances in the network in a week had increased from nine instances two weeks ago to seven last week.
Meanwhile, two of the six imported reported on Saturday were permanent citizens who had returned from India on 12 July and the United Kingdom on 10 July.
The 4 imported patients are dependent pass holders who arrived from India between 11 and 13 July, joined by a three-year-old, an Indian citizen who had no symptoms.
Human trials of a COVID-19 vaccine can begin in Singapore this week, with 108 healthy volunteers of other ages, the Sunday Times reported.
Volunteers will get an injection of the vaccine developed through Duke-NUS Medical School and the US pharmaceutical company Arcturus Therapeutics.
Called Lunar-Cov19, the vaccine is one of 25 candidate vaccines in the world that have been tested on humans or been authorized to do so. Another 141 are still in the preclinical phase.
Professor Ooi Eng Eong, deputy director of the Emerging Infectious Diseases Program at Duke-NUS School of Medicine, told the Sunday Times that the purpose of the trial was to protect the vaccine and whether it could convince the desired immune reaction under the framework. opposite Sars-CoV-2, the guilty VIRUS of COVID-19.
Blood samples will be taken from volunteers after vaccination for testing.
Because elements of the immune formula, such as antibodies and T cells, are discovered in the blood, knowledge will help scientists determine whether the vaccine manages to stimulate the framework for producing the “soldiers” needed to help the framework fight an infection.
Recently published results from human trials for other vaccine candidates have already shown encouraging signs on these fronts.
The effects came from the early stages of clinical trials of vaccines evolved through the University of Oxford and the multinational drug manufacturer AstraZeneca; CanSino Biologics and the China Military Research Unit; and the German biotechnology company BioNTech and the US drug manufacturer Pfizer.
Professor Eong said he was confident that the effects of the Singapore trial would produce similar encouraging effects.]
This story was published from a firm thread without converting the text. Only the name has been changed.
Click here to read Mint ePaperLivemint.com is now on Telegram. Join the Livemint channel on your telegram and updated
Log in to our to save your favorites. It’ll only take a moment.
Your query has expired, reconnect.
You are now subscribed to our newsletters. If you can’t find any email from us, check your spam folder.